"Use of S1P receptor modulator"

Details for Australian Patent Application No. 2012200503 (hide)

Owner Novartis AG

Inventors Mir, Anis Khusro; Schubart, Anna Svenja; Bilbe, Graeme; Barde, YvesAlain; Deogracias, Ruben; Matsumoto, Tomoya; Kuhn, Rainer R.

Agent Davies Collison Cave

Pub. Number AU-A-2012200503

Parent 2008248648

Filing date 30 January 2012

Wipo publication date 23 February 2012

International Classifications

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

16 February 2012 Complete Application Filed

23 February 2012 Application Open to Public Inspection

  Published as AU-A-2012200503

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012200504-Thermal power plant with carbon dioxide capture scrubbing equipment

2012200502-System and method for intelligent casino configuration